| IDNA Etf | | | USD 22.45 0.54 2.46% |
This module uses fundamental data of IShares Genomics to approximate its Piotroski F score. IShares Genomics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of iShares Genomics Immunology. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about IShares Genomics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out
IShares Genomics Altman Z Score,
IShares Genomics Correlation,
Portfolio Optimization, as well as analyze
IShares Genomics Alpha and Beta and
IShares Genomics Hype Analysis.
At this time, it appears that IShares Genomics' Piotroski F Score is Inapplicable. Although some professional money managers and academia have recently criticized
Piotroski F-Score model, we still consider it an effective method of
predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
0.0
Piotroski F Score - Inapplicable
| Change in Return on Assets | |
| Cash Flow Return on Assets | |
| Current Quality of Earnings (accrual) | |
| Long Term Debt Over Assets Change | |
| Change In Outstending Shares | |
IShares Genomics Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to IShares Genomics is to make sure IShares is not a subject of accounting manipulations and runs a healthy internal audit department. So, if IShares Genomics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if IShares Genomics' financial numbers are properly reported.
About IShares Genomics Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled
Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
About IShares Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze iShares Genomics Immunology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IShares Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at
the intrinsic value of iShares Genomics Immunology based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing
financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our
fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether iShares Genomics Imm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IShares Genomics'
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ishares Genomics Immunology Etf.
Outlined below are crucial reports that will aid in making a well-informed decision on Ishares Genomics Immunology Etf: The market value of iShares Genomics Imm is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Genomics' value that differs from its market value or its book value, called intrinsic value, which is IShares Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Genomics' market value can be influenced by many factors that don't directly affect IShares Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.